Incyte Corporation (INCY) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at...

Form 144 - Report of proposed sale of securities

Aktuelle Incyte Tafasitamab (Monjuvi® ) Daten demonstrieren auf dem ASH 2024 deutlich verbessertes progressionsfreies Überleben bei Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom

Die inMIND-Phase-III-Schlüsselstudie hat ihren primären Endpunkt des progressionsfreien Überlebens (PFS) und wichtige sekundäre Endpunkte bei...

Les données de dernières minutes d'Incyte sur le tafasitamab (Monjuvi®) à l'ASH 2024 démontrent une survie sensiblement améliorée de la survie sans progression chez les patients atteints de lymphome folliculaire récidivant ou réfractaire

L'essai pivot de phase 3 inMIND a atteint son critère principal de survie sans progression (SSP) et ses critères secondaires clés chez les...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with...

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated...

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities